Grace Collins | July 18, 2025
Stakeholder Connect | Insights from the July 17, 2025 Meeting of the Oncologic Drugs Advisory Committee (ODAC)
What was the committee asked to consider? On July 17, 2025, the U.S. Food and Drug Administration (FDA) convened the Oncologic Drugs Advisory Committee (ODAC) to vote on whether the overall benefit-risk profile of two new combination regimens (belantamab mafodotin + bortezomib + dexamethasone [BVd] and belantamab mafodotin + pomalidomide + dexamethasone [BPd]) for treatment…
Read More